Modulation of thalidomide pharmacokinetics by cyclophosphamide or 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice: the role of tumour necrosis factor

By Chung Francisco   Wang Liang-Chuan   Kestell Philip   Baguley Bruce   Ching Lai-Ming  

Cancer Chemotherapy and Pharmacology, Vol. 53, Iss. 5, 2004-05 ,pp. : 377-383

Springer Publishing Company

Access to resources Recommend Favorite

Gender differences in the metabolism and pharmacokinetics of the experimental anticancer agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA)

By Zhou Shufeng   Kestell Philip   Tingle Malcolm   Paxton James  

Cancer Chemotherapy and Pharmacology, Vol. 49, Iss. 2, 2002-02 ,pp. : 126-132

Springer Publishing Company

Access to resources Recommend Favorite

The antitumour agent 5,6-dimethylxanthenone-4-acetic acid acts in vitro on human mononuclear cells as a co-stimulator with other inducers of tumour necrosis factor

By Philpott M.   Ching L.-M.   Baguley B.C.  

European Journal of Cancer, Vol. 37, Iss. 15, 2001-10 ,pp. : 1930-1937

Elsevier

Access to resources Recommend Favorite

Potentiation of the anti-tumour effect of hyperthermia by combining with the vascular targeting agent 5,6-dimethylxanthenone-4-acetic acid

By Murata R.   Overgaard J.   Horsman M. R.  

International Journal of Hyperthermia, Vol. 17, Iss. 6, 2001-11 ,pp. : 508-519

Informa Healthcare

Access to resources Recommend Favorite

Tumour-specific enhancement of thermoradiotherapy at mild temperatures by the vascular targeting agent 5,6-dimethylxanthenone-4-acetic acid

By Murata R.   Horsman M. R.  

International Journal of Hyperthermia, Vol. 20, Iss. 4, 2004-06 ,pp. : 393-404

Informa Healthcare

Access to resources Recommend Favorite